Breakthrough cancer pain: a comparison of surveys with European and Canadian patients

详细信息    查看全文

• 作者：Gillian Bedard ; Andrew Davies ; Rachel McDonald…
• 关键词：Breakthrough pain ; Cancer ; Patients-perspectives
• 刊名：Supportive Care in Cancer
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：23
• 期：3
• 页码：791-796
• 全文大小：132 KB
• 参考文献：1. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18(9):1437-449 CrossRef
  2. World Health Organization. WHO’s cancer pain ladder for adults. 2014; Available at: painladder/en/" class="a-plus-plus">http://www.who.int/cancer/palliative/painladder/en/. Accessed 10 March 2014
  3. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13(4):331-38 pain.2008.06.014" target="_blank" title="It opens in new window">CrossRef
  4. Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F et al (2002) Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94(3):832-39 CrossRef
  5. Webber K, Davies AN, Cowie MR (2011) Breakthrough pain: a qualitative study involving patients with advanced cancer. Support Care Cancer 19(12):2041-046 CrossRef
  6. Mercadante S, Ferrera P, Adile C, Casuccio A (2011) Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manag 42(3):464-69 painsymman.2010.12.010" target="_blank" title="It opens in new window">CrossRef
  7. Mercadante S (2012) Pharmacotherapy for breakthrough cancer pain. Drugs 72(2):181-90 CrossRef
  8. Bedard G, Hawley P, Zhang L, Slaven M, Gagnon P, Bisland S et al (2013) A survey of Canadian cancer patients-perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer 21(9):2557-563 CrossRef
  9. Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W et al (2013) Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag 46(5):619-28 painsymman.2012.12.009" target="_blank" title="It opens in new window">CrossRef
  10. Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G (2014) Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manag 47(1):57-6 painsymman.2013.02.015" target="_blank" title="It opens in new window">CrossRef
  11. Davis MP (2011) Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother 11(8):1197-216 CrossRef
  12. Mercadante S, Arcuri E (2007) Pharmacological management of cancer pain in the elderly. Drugs Aging 24(9):761-76 CrossRef
  13. Davies A, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, Nauck F et al (2011) Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 15(7):756-63 pain.2010.12.004" target="_blank" title="It opens in new window">CrossRef
  14. Black B, Herr K, Fine P, Sanders S, Tang X, Bergen-Jackson K et al (2011) The relationships among pain, nonpain symptoms, and quality of life measures in older adults with cancer receiving hospice care. Pain Med 12(6):880-89 CrossRef
  15. Ferrell BR, Juarez G (2002) Cancer pain education for patients and the public. J Pain Symptom Manag 23(4):329-36 CrossRef
  16. Ward
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Nursing
  Nursing Management and Research
  Pain Medicine
  Rehabilitation Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-7339

文摘

Introduction Breakthrough cancer pain is defined as a transient exacerbation of pain that occurs spontaneously or in response to a trigger, despite stable and controlled background pain. Breakthrough pain often causes significant functional impairments for patients and can decrease quality of life. Objective The objective of the study was to determine differences between breakthrough cancer pain incidence and management in Canada and Europe. Methods Data collected from previous studies of breakthrough cancer pain in Canada and Europe was compared. A standard survey with identical inclusion/exclusion criteria was utilized for both patient populations. Results Both groups of patients had a similar number and duration of breakthrough pain episodes, and similar pain intensity and pain interference with their daily activities. European patients reported better analgesic efficacy and satisfaction with management, and a greater percentage of European patients were prescribed a transmucosal fentanyl formulation (19.1 vs 2.9?%). More European patients (55?%) than Canadian patients (32.5?%) took their rescue medication every time they had a breakthrough pain episode. Conclusions Breakthrough cancer pain in both Canadian and European patients greatly impacts their daily living, and both groups of patients had similar experiences with breakthrough cancer pain. Currently, this pain is not adequately managed for many patients. The role for new analgesic treatments in management of breakthrough cancer pain needs further study.